Online citations, reference lists, and bibliographies.
← Back to Search

Non-cosmetic Botulinum Toxin Treatments In The Head And Neck

L. Madden, C. Rosen
Published 2018 · Medicine

Cite This
Download PDF
Analyze on Scholarcy
Share
Treatment of dystonias in the head and neck can be challenging for even the most experienced otolaryngologist. Available oral therapeutic options often fail to provide improvement in many patients and oftentimes come with intolerable systemic side effects that limit their use. With the introduction of botulinum toxin (BTX) to the treatment armamentarium for patients with dystonias, patients would have the chance for treatment by targeting only focal areas. With the use of BTX, treating physicians can focus treatment to only areas affected by the dystonia. This greatly minimizes the occurrence of systemic side effects. In this chapter, we will present a review of the history of the medical applications of BTX and discuss its role in the treatment of various dystonias of the head and neck.
This paper references
10.1212/WNL.36.2.160
Torsion dystonia
R. Burke (1986)
10.1016/j.otohns.2006.04.001
Frozen versus fresh reconstituted botox for laryngeal dystonia
J. Thomas (2006)
10.1001/ARCHOTOL.124.10.1133
Vagal paraganglioma: a review of 46 patients treated during a 20-year period.
J. Netterville (1998)
10.1007/s00106-010-2223-6
[The incidence of Frey syndrome following parotidectomy: results of a survey and follow-up].
A. Neumann (2011)
10.1080/14764170260030126
Botulinum B treatment of the glabellar and frontalis regions: a dose response analysis
James M. Spencer (2002)
10.1097/01.PRS.0000082197.88799.84
The Role of Botulinum Toxin Type B (Myobloc) in the Treatment of Hyperkinetic Facial Lines
E. Kim (2003)
10.1016/j.jaad.2007.11.015
Potency of the botulinum toxin product CNBTX-A significantly exceeds labeled units in standard potency test.
Terrence Hunt (2008)
10.1007/s00266-004-0062-0
Evaluating Effects of Preservative-Containing Saline Solution on Pain Perception During Botulinum Toxin Type-A Injections at Different Locations: A Prospective, Single-Blinded, Randomized Controlled Trial
N. Sarıfakioğlu (2004)
10.1067/MJD.2000.105567
Pharmacology of botulinum toxin.
W. Huang (2000)
10.1007/s00106-010-2223-6
Inzidenz des Frey-Syndroms nach Parotidektomie
A. Neumann (2010)
Use of botulinum toxin type A in the treatment of cervical dystonia.
C. Comella (2000)
10.1016/J.OTC.2004.01.003
Management of pharyngoesophageal spasm with Botox.
S. Chao (2004)
The first-bite syndrome.
W. S. Haubrich (1986)
10.1016/b0-443-07287-6/50008-4
Inflammatory mediators and modulators of pain
S. McMahon (2005)
10.1016/S0161-6420(80)35127-0
Botulinum toxin injection into extraocular muscles as an alternative to strabismus surgery.
A. B. Scott (1980)
10.1097/01.PRS.0000082195.44980.10
The Effect of Botulinum Toxin Injections on the Nasolabial Fold
M. Kane (2003)
10.1002/MDS.870030302
Epidemiology of focal and generalized dystonia in Rochester, Minnesota
J. Nutt (1988)
10.1046/J.0007-1323.2001.01982.X
Botulinum toxin A in the treatment of patients with Frey syndrome
A. J. Beerens (2002)
10.1212/WNL.48.1.249
Reconstituted Botulinum Toxin Type A Does Not Lose Potency in Humans If It Is Refrozen or Refrigerated for 2 Weeks Before Use
R. Sloop (1997)
10.1016/S0194-5998(99)70268-8
Botulinum Toxin Injection to Improve Tracheoesophageal Speech after Total Laryngectomy
M. Zormeier (1999)
10.1002/hed.21054
Novel treatment of first bite syndrome using botulinum toxin type A
B. Lee (2009)
10.1111/j.1524-4725.2011.02087.x
Handling Botulinum Toxins: An Updated Literature Review
Ada R. Trindade De Almeida (2011)
10.1212/WNL.41.11.1800
Botulinum‐induced alteration of nerve‐muscle interactions in the human orbicularis oculi following treatment for blepharospasm
K. Alderson (1991)
10.1111/j.1524-4725.1998.tb04094.x
Dilution and Storage of Botulinum Toxin
A. Klein (1998)
10.1053/SDER.2003.50009
Botulinum neurotoxin type B--a rapid wrinkle reducer.
C. Jacob (2003)
10.1016/S0151-9638(06)70842-0
Granulomes sarcoïdosiques après injections de toxine botulique A (Botox®) pour correction de rides
S. Ahbib (2006)
10.1016/S0194-5998(95)70002-1
Voice failure after tracheoesophageal puncture: management with botulinum toxin.
A. Blitzer (1995)
10.1002/lary.25068
Safety and efficacy of multiuse botulinum toxin vials for intralaryngeal injection
Emily M. Barrow (2015)
10.1212/01.WNL.0000055087.96356.BB
Comparison of efficacy and immunogenicity of original versus current botulinum toxin in cervical dystonia
J. Jankovic (2003)
10.4065/75.7.701
Addition of an anesthetic agent to enhance the predictability of the effects of botulinum toxin type A injections: a randomized controlled study.
H. Gassner (2000)
10.1002/lary.25273
Botulinum toxin management of spasmodic dysphonia (laryngeal dystonia): A 12‐year experience in more than 900 patients
A. Blitzer (2015)
10.1080/14764170701411470
The evolution of botulinum neurotoxin type A for cosmetic applications
J. Carruthers (2007)
10.1177/019459989310800205
Crystalline Preparation of Botulinum Toxin Type a (Botox): Degradation in Potency with Storage
M. Gartlan (1993)
10.1097/NRL.0b013e318095a4d5
Pearls in Patient Selection for Deep Brain Stimulation
R. Rodríguez (2007)
10.1001/ARCHOPHT.1985.01050090057031
Hemifacial spasm treated with botulinum A toxin injection.
P. Savino (1985)
10.1212/WNL.53.7.1431
Safety and efficacy of NeuroBloc (botulinum toxin type B) in type A-responsive cervical dystonia.
A. Brashear (1999)
10.1016/S0161-6420(88)32977-5
Long-term results and complications of botulinum A toxin in the treatment of blepharospasm.
J. Dutton (1988)
10.1002/HED.1059
Further experience with botox injection for tracheoesophageal speech failure
J. Lewin (2001)
10.1002/ANA.410110108
Treatment of hyperkinetic movement disorders with tetrabenazine: A double‐blind crossover study
J. Jankovic (1982)
10.1097/01.IOP.0000129012.09632.49
Increased Patient Comfort Utilizing Botulinum Toxin Type A Reconstituted with Preserved Versus Nonpreserved Saline
D. M. Kwiat (2004)
10.1097/00002826-198600092-00005
Generalized Dystonia: Concept and Treatment
S. Fahn (1986)
10.1097/01.WNF.0000236771.77021.3C
A Double-blind, Randomized, Crossover Study of Prosigne Versus Botox in Patients With Blepharospasm and Hemifacial Spasm
C. Rieder (2007)
10.1111/j.1471-4159.2009.06093.x
Cell entry strategy of clostridial neurotoxins
T. Binz (2009)
10.1097/00002826-199208000-00002
Baclofen in the treatment of dystonia.
P. Greene (1992)
10.3109/00016489509139348
Frey's syndrome: treatment with botulinum toxin.
C. Drobik (1995)
10.1016/S0002-9343(03)00259-6
Essential tremor: differential diagnosis and current therapy.
R. Pahwa (2003)
10.1067/mhn.2000.106400
Videostroboscopy of the Pharyngoesophageal Segment in Laryngectomy Patients Treated With Botulinum Toxin
R. Meleca (2000)
10.1002/mds.20376
Long‐term botulinum toxin efficacy, safety, and immunogenicity
Nicte I. Mejia (2005)
10.1097/00005537-200309000-00010
Botulinum Neurotoxin for Pharyngeal Constrictor Muscle Spasm in Tracheoesophageal Voice Restoration
R. Hamaker (2003)
10.1002/MDS.870120637
Idiosyncratic adverse reactions to intramuscular botulinum toxin type a injection
P. Lewitt (1997)
10.1111/j.1365-2133.2007.07760.x
Treatment of axillary hyperhidrosis with botulinum toxin type A reconstituted in lidocaine or in normal saline: a randomized, side‐by‐side, double‐blind study
J. Vadoud-Seyedi (2007)
10.1520/JFS2004196
Fatal case of BOTOX-related anaphylaxis?
M. Li (2005)
10.1007/s10072-011-0560-1
Botulinum toxin type A: an effective treatment to restore phonation in laryngectomized patients unable to voice
L. Bartolomei (2011)
10.1001/archoto.2008.545
Repeated botulinum toxin type A injections to treat patients with Frey syndrome.
R. de Bree (2009)
10.1016/j.asj.2009.09.016
Botulinum neurotoxin type A-ABO (Dysport): clinical indications and practice guide.
A. Matarasso (2009)
10.1177/019459989310900537
Potency of Frozen/Thawed Botulinum Toxin Type a in the Treatment of Torsion Dystonia
P. Greene (1993)
Hyaluronic acid filler and botulinum Neurotoxin delivered simultaneously in the same syringe for effective and convenient combination aesthetic rejuvenation therapy.
Julie R Kenner (2010)
10.1097/01.mlg.0000233255.57425.36
Development and Validation of the Vocal Tremor Scoring System
M. Bové (2006)
10.1002/hed.10162
First bite syndrome: A complication of surgery involving the parapharyngeal space
A. Chiu (2002)
10.1159/000083259
Botulinum Toxin: Mechanisms of Action
D. Dressler (2005)
In vitro characterization of botulinum toxin types A, C and D action on human tissues: combined electrophysiologic, pharmacologic and molecular biologic approaches.
J. Coffield (1997)
10.1055/s-0031-1298784
Neuromodulators: available agents, physiology, and anatomy.
Kartik D Nettar (2011)
10.1002/ANA.410130406
Blepharospasm and orofacial‐cervical dystonia: Clinical and pharmacological findings in 100 patients
J. Jankovic (1983)
10.1001/ARCHOPHT.1985.01050030043017
Botulinum A toxin injection as a treatment for blepharospasm.
A. Scott (1985)
10.1002/mds.21724
Botulinum toxin type B vs. type A in toxin‐naïve patients with cervical dystonia: Randomized, double‐blind, noninferiority trial
E. Pappert (2008)
10.1002/lary.24073
A new paradigm for the management of essential vocal tremor with botulinum toxin
Lowell E Gurey (2013)
10.1001/archfaci.10.4.273
Questioning the need to use Botox within 4 hours of reconstitution: a study of fresh vs 2-week-old Botox.
G. C. Yang (2008)
10.1212/WNL.40.1.66
Dopa‐responsive dystonia
T. Nygaard (1990)
10.1055/S-0030-1249406
Simultane Injektion mit Lidocain verbessert die Vorhersehbarkeit des Effekts von Botulinumtoxin
F. Haubner (2010)
10.1002/mds.22336
Respective potencies of Botox® and Dysport® in a human skin model: A randomized, double‐blind study
G. Kranz (2009)
10.1016/j.otohns.2010.04.009
Treatment of Frey's syndrome with botulinum toxin type B
Giovanna Cantarella (2010)
10.1016/j.otohns.2009.01.026
Recommendations of the Neurolaryngology Study Group on laryngeal electromyography
A. Blitzer (2009)
10.2165/00003495-200767050-00003
Botulinum Neurotoxin Type A Free of Complexing Proteins (XEOMIN®) in Focal Dystonia
W. Jost (2012)



Semantic Scholar Logo Some data provided by SemanticScholar